ArticleCell reports. Medicine2021
Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer.
Open access · goldAbstract read
In one paragraph
Article in Cell reports. Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
5.2field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 71 citations in OpenAlex.
- Subtype-specific mechanisms of lipid metabolism in gynecological malignancies and novel targeted intervention strategies (Review).Oncology letters · 2026Review
- CPT1A through succinylation regulates the CTCF/LINC01503‒91aa feedback loop to promote gemcitabine resistance in pancreatic ductal adenocarcinoma.Clinical and translational medicine · 2026Article
- Carboxylesterase 1 is a core metabolic vulnerability of platinum-resistant high-grade serous ovarian carcinoma.Journal of experimental & clinical cancer research : CR · 2026Article
- CRISPR-Cas9: Genome Engineering and Future Vaccine Applications.Molecular biotechnology · 2026Review
- CPT1A drives cisplatin resistance via acetylation‑dependent activation of DRP1 and mitochondrial fission in small cell lung cancer.Cell death & disease · 2026Article
- Platinum-resistant ovarian cancer: From mechanisms to treatment strategies.Genes & diseases · 2026Review
- Acylcarnitines in Cancer Metabolism: Mechanistic Insights and Stratification Potential.Cancers · 2026Review
- Role of the tumor microenvironment in chemotherapy resistance in ovarian cancer and targeted therapy.Journal of ovarian research · 2025Review
- Bidirectional crosstalk between ER stress and lipid metabolism: From proteostasis to tumor adaptation.Cell death discovery · 2025Review
- Novel therapeutic strategies for targeting fatty acid oxidation in cancer.Biomarker research · 2025Review
- Emerging roles for fatty acid oxidation in cancer.Genes & diseases · 2025Review
- Spatially resolved proteomics surveys the chemo-refractory proteins related to high-grade serous ovarian cancer.Clinical and translational medicine · 2025Article
- The role and mechanism of fatty acid oxidation in cancer drug resistance.Cell death discovery · 2025Review
- Neutrophil extracellular traps induced by neoadjuvant chemotherapy of breast cancer promotes vascular endothelial damage.Breast cancer research : BCR · 2025Article
- CRISPR/Cas9 system: a novel approach to overcome chemotherapy and radiotherapy resistance in cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Crosstalk between stromal, immune, and ovarian cancer cells in lipid-rich tumor microenvironment exhibits proliferative features.Frontiers in immunology · 2025Review
- Therapeutic Targeting in Ovarian Cancer: Nano-Enhanced CRISPR/Cas9 Gene Editing and Drug Combination Therapy.International journal of nanomedicine · 2025Review
- The solid tumor microenvironment and related targeting strategies: a concise review.Frontiers in immunology · 2025Review
- GSTP1 knockdown induces metabolic changes affecting energy production and lipid balance in pancreatic cancer cells.Molecular & cellular oncology · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 10 institutions in 1 country.
Dongqing HuangClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Shrabanti ChowdhuryDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Hong WangClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Sara R SavageLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA.
Richard G IveyClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Jacob J KennedyClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Jeffrey R WhiteakerClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Chenwei LinClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Xiaonan HouDepartment of Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Ann L ObergDepartment of Quantitative Health Sciences, Division of Computational Biology, Mayo Clinic, Rochester, MN 55905, USA.
Melissa C LarsonDepartment of Quantitative Health Sciences, Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN 55905, USA.
Najmeh EskandariDivision of Hematology and Oncology, Department of Medicine, University of Illinois, Chicago, IL 60612, USA.
Davide A DelisiDivision of Hematology and Oncology, Department of Medicine, University of Illinois, Chicago, IL 60612, USA.
Saverio GentileDivision of Hematology and Oncology, Department of Medicine, University of Illinois, Chicago, IL 60612, USA.
Catherine J HuntoonDepartment of Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Uliana J VoytovichClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Zahra J ShireClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Qing YuDepartment of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.
Steven P GygiDepartment of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.
Andrew N HoofnagleDepartment of Lab Medicine, University of Washington, Seattle, WA 98195, USA.
Zachary T HerbertMolecular Biology Core Facilities, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Travis D LorentzenClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Anna CalinawanDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Larry M KarnitzDepartment of Oncology, Mayo Clinic, Rochester, MN 55905, USA.
S John WerohaDepartment of Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Scott H KaufmannDepartment of Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Bing ZhangLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA.
Pei WangDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Michael J BirrerUniversity of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Amanda G PaulovichClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Fred Hutch Cancer Center · USMayo Clinic in Arizona · USIcahn School of Medicine at Mount Sinai · USUniversity of Illinois Chicago · USBaylor College of Medicine · USHarvard University · USMayo Clinic in Florida · USDana-Farber Cancer Institute · USUniversity of Arkansas for Medical Sciences · USUniversity of Washington · US
Funding
Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3MUse of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI ELLEN L. GOODE · 2009 to 2026
$37.0MProteogenomic Studies aimed at understanding ovarian tumor responses to agents targeting the DNA damage response and translating this knowledge into clinical benefitU01CA214114 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BIRRER, MICHAEL, PAULOVICH, AMANDA G · 2017 to 2021
$8.4MiPGDAC, An Integrative Proteogenomic Data Analysis Center for CPTACU24CA210954 · NCI · BAYLOR COLLEGE OF MEDICINE · PI ZHANG, BING · 2016 to 2020
$4.9MSystems Biology based Proteogenomic Translator for Cancer Marker Discovery towards Precision MedicineU24CA210993 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI SCHADT, ERIC E, WANG, PEI · 2016 to 2020
$4.6MA proteomics research specialist in developing targeted mass spectrometry methods for quantifying proteins important in cancerR50CA211499 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Jeff Whiteaker · 2016 to 2026
$2.8MHigh-Performance Compute Cluster for Comprehensive Cancer and Infectious Diseases ResearchS10OD028685 · OD · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BRADLEY, PHILIP · 2020 to 2020
$2.0MNCI NIH HHS P30 CA015083NCI NIH HHS P50 CA136393NCI NIH HHS R50 CA211499NCI NIH HHS U01 CA214114NCI NIH HHS U24 CA210954NCI NIH HHS U24 CA210993NIH HHS S10 OD028685
Abstract
Resistance to platinum compounds is a major determinant of patient survival in high-grade serous ovarian cancer (HGSOC). To understand mechanisms of platinum resistance and identify potential therapeutic targets in resistant HGSOC, we generated a data resource composed of dynamic (±carboplatin) protein, post-translational modification, and RNA sequencing (RNA-seq) profiles from intra-patient cell line pairs derived from 3 HGSOC patients before and after acquiring platinum resistance. These profiles reveal extensive responses to carboplatin that differ between sensitive and resistant cells. Higher fatty acid oxidation (FAO) pathway expression is associated with platinum resistance, and both pharmacologic inhibition and CRISPR knockout of
Indexed as
GenomicsMolecular Targeted TherapyAcetyl-CoA CarboxylaseAnimalsApoptosisCarboplatinCarnitine O-PalmitoyltransferaseCell Line, TumorCell ProliferationCystadenocarcinoma, SerousDNA DamageDrug Resistance, NeoplasmFatty AcidsFemaleGene Expression Regulation, NeoplasticHumansACACB protein, humanAcetyl-CoA CarboxylaseCarboplatinCarnitine O-PalmitoyltransferaseCPT1A protein, humanFatty AcidsPhosphoproteinsReactive Oxygen SpeciescarboplatinCPT1Afatty acid oxidationovarian canceroxidative phosphorylationproteogenomicproteomicreactive oxygen speciesresistance
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.